Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success

被引：0
|
作者：
Regan, M. M.
Dafni, U.
Karlis, D.
Goldhirsch, A.
Untch, M.
Smith, I.
Gianni, L.
Jackisch, C.
de Azambuja, E.
Heinzmann, D.
Cameron, D.
Bell, R.
Dowsett, M.
Baselga, J.
Leyland-Jones, B.
Piccart-Gebhart, M. J.
Gelber, R. D.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Athens, Athens, Greece
[3] Frontier Sci Fdn Hellas, Athens, Greece
[4] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[5] Helios Klinikum Berlun Buch, Berlin, Germany
[6] Royal Marsden Hosp, London SW3 6JJ, England
[7] Inst Canc Res, London SW3 6JB, England
[8] San Raffaele Inst, Milan, Italy
[9] Western Gen Hosp, Edinburgh, Midlothian, Scotland
[10] Univ Edinburgh, Edinburgh EH8 9YL, Midlothian, Scotland
[11] Royal Marsden NHS Trust, London, England
[12] European Inst Oncol, Milan, Italy
[13] Athens Univ Econ, Athens, Greece
[14] Massachusetts Gen Hosp, Boston, MA 02114 USA
[15] F Hoffmann La Roche, Basel, Switzerland
[16] Sanford Res, Sioux Falls, SD USA
[17] Geelong Hosp, Andrew Love Canc Ctr, Geelong, Vic, Australia
[18] Klinikum Offenbach, Offenbach, Germany
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-P5-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-18-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ongoing adjuvant trials with trastuzumab in breast cancer
    Tan, AR
    Swain, SM
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 54 - 64
  • [2] Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
    Slamon, D
    Pegram, M
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 13 - 19
  • [3] Crossover in Adjuvant Trastuzumab Trials Sparing Toxicity in Patient Care
    Tuia, Jordan E.
    Olivier, Timothee
    Prasad, Vinay K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (10): : 438 - 441
  • [4] RANDOMIZED ADJUVANT BREAST-CANCER TRIALS IN SWEDEN
    RUTQVIST, LE
    CANCER, 1994, 74 (03) : 1156 - 1159
  • [5] Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials
    Brollo, Janaina
    Curigliano, Giuseppe
    Disalvatore, Davide
    Marrone, Bianca Fontana
    Criscitiello, Carmen
    Bagnardi, Vincenzo
    Kneubil, Maximiliano Cassilha
    Fumagalli, Luca
    Locatelli, Marzia
    Manunta, Silvia
    Goldhirsch, Aron
    CANCER TREATMENT REVIEWS, 2013, 39 (01) : 44 - 50
  • [6] Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
    Saroj Niraula
    Bishal Gyawali
    Breast Cancer Research and Treatment, 2019, 173 : 103 - 109
  • [7] Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
    Niraula, Saroj
    Gyawali, Bishal
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (01) : 103 - 109
  • [8] Adjuvant trastuzumab for breast cancer outside of clinical trials: Cardiotoxicity and economic evaluation
    Snow, S.
    Skedgel, C.
    Rayson, D.
    Thompson, K.
    Sellon, M.
    Barnes, P.
    Jeyakumar, A.
    Younis, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Adjuvant trastuzumab in early breast cancer
    Mariani, G.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2006, 17 : X54 - X58
  • [10] Trastuzumab in the adjuvant treatment of breast cancer
    Svetlovska, D.
    Mardiak, J.
    Kristova, V
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2007, 108 (02): : 100 - 103
12345